Ex Vivo-Expanded Cynomolgus Macaque Regulatory T Cells Are Resistant to Alemtuzumab-Mediated Cytotoxicity

Hale, 1990, The CAMPATH-1 antigen (CDw52), Tissue Antigens, 35, 118, 10.1111/j.1399-0039.1990.tb01767.x Hale, 1988, Remission induction in non-Hodgkin lymphoma with reshaped human monoclonal antibody CAMPATH-1H, Lancet, 2, 1394, 10.1016/S0140-6736(88)90588-0 Shapiro, 2005, Kidney transplantation under minimal immunosuppression after pretransplant lymphoid depletion with thymoglobulin or Campath, J Am Coll Surg, 200, 505, 10.1016/j.jamcollsurg.2004.12.024 Hu, 2009, Investigation of the mechanism of action of alemtuzumab in a human CD52 transgenic mouse model, Immunology, 128, 260, 10.1111/j.1365-2567.2009.03115.x Lowenstein, 2006, Different mechanisms of Campath-1H-mediated depletion for CD4 and CD8 T cells in peripheral blood, Transpl Int, 19, 927, 10.1111/j.1432-2277.2006.00382.x Morris, 2003, Pharmacokinetics of alemtuzumab used for in vivo and in vitro T-cell depletion in allogeneic transplantations: Relevance for early adoptive immunotherapy and infectious complications, Blood, 102, 404, 10.1182/blood-2002-09-2687 Wood, 2003, Regulatory T cells in transplantation tolerance, Nat Rev Immunol, 3, 199, 10.1038/nri1027 Bluestone, 2005, Regulatory T-cell therapy: Is it ready for the clinic?, Nat Rev Immunol, 5, 343, 10.1038/nri1574 Walsh, 2004, Tregs and transplantation tolerance, J Clin Invest, 114, 1398, 10.1172/JCI200423238 Jiang, 2003, Regulatory T cells in the control of transplantation tolerance and autoimmunity, Am J Transplant, 3, 516, 10.1034/j.1600-6143.2003.00124.x Wood, 2012, Regulatory immune cells in transplantation, Nat Rev Immunol, 12, 417, 10.1038/nri3227 Raimondi, 2010, Mammalian target of rapamycin inhibition and alloantigen-specific regulatory T cells synergize to promote long-term graft survival in immunocompetent recipients, J Immunol, 184, 624, 10.4049/jimmunol.0900936 Bloom, 2008, CD4+ CD25+ FOXP3+ regulatory T cells increase de novo in kidney transplant patients after immunodepletion with Campath-1H, Am J Transplant, 8, 793, 10.1111/j.1600-6143.2007.02134.x Pascual, 2008, Calcineurin inhibitor withdrawal after renal transplantation with alemtuzumab: Clinical outcomes and effect on T-regulatory cells, Am J Transplant, 8, 1529, 10.1111/j.1600-6143.2008.02260.x Macedo, 2012, Long-term effects of alemtuzumab on regulatory and memory T-cell subsets in kidney transplantation, Transplantation, 93, 813, 10.1097/TP.0b013e318247a717 Brunstein, 2011, Infusion of ex vivo expanded T regulatory cells in adults transplanted with umbilical cord blood: Safety profile and detection kinetics, Blood, 117, 1061, 10.1182/blood-2010-07-293795 Lopez, 2006, A novel mechanism of action for anti-thymocyte globulin: Induction of CD4+CD25+Foxp3+ regulatory T cells, J Am Soc Nephrol, 17, 2844, 10.1681/ASN.2006050422 van der Windt, 2010, Investigation of lymphocyte depletion and repopulation using alemtuzumab (Campath-1H) in cynomolgus monkeys, Am J Transplant, 10, 773, 10.1111/j.1600-6143.2010.03050.x Perry, 1992, Identification of an abundant monkey epididymal transcript encoding a homologue of human CAMPATH-1 antigen precursor, Biochim Biophys Acta, 1171, 122, 10.1016/0167-4781(92)90152-P Yeung, 1997, Interaction of the human epididymal protein CD52 (HE5) with epididymal spermatozoa from men and cynomolgus monkeys, Mol Reprod Dev, 48, 267, 10.1002/(SICI)1098-2795(199710)48:2<267::AID-MRD15>3.0.CO;2-V Liu, 2006, CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+ T reg cells, J Exp Med, 203, 1701, 10.1084/jem.20060772 Dons, 2012, Induced regulatory T cells: Mechanisms of conversion and suppressive potential, Hum Immunol, 73, 328, 10.1016/j.humimm.2011.12.011 Levitsky, 2012, Favorable effects of alemtuzumab on allospecific regulatory T-cell generation, Hum Immunol, 73, 141, 10.1016/j.humimm.2011.11.008 Zou, 2004, Bone marrow is a reservoir for CD4+CD25+ regulatory T cells that traffic through CXCL12/CXCR4 signals, Cancer Res, 64, 8451, 10.1158/0008-5472.CAN-04-1987 Lim, 2008, Effect of anti-CD52 antibody alemtuzumab on ex-vivo culture of umbilical cord blood stem cells, J Hematol Oncol, 1, 19, 10.1186/1756-8722-1-19